Gene-based AMD treatment shows potential

www.prooftalmoclinica.com.br - oftalmologia
Gene-based AMD treatment shows potential
Categoria : News
Publicado por Admin em 06/7/2011
Gene-based AMD treatment shows potential
A gene-based treatment for age-related macular degeneration (AMD) demonstrated safety and
tolerability at 1 month in a Phase I study, developer Oxford BioMedica (Oxford, U.K.) said in a news
release.
RetinoStat is designed to treat wet AMD using the company’s proprietary LentiVector gene delivery
technology, and is part of the development agreement between Oxford and Sanofi (Paris).
The ongoing Phase I study will enroll 18 patients with wet AMD at the Wilmer Eye Institute
(Baltimore). The study will evaluate three dose levels and evaluate safety, aspects of visual acuity,
and ocular physiology. The preliminary 1-month results, which evaluated the first dose level in three
patients, found RetinoStat to have a favorable safety profile with no serious adverse events or signs
of inflammation in the eye. In addition, Oxford BioMedica has begun a Phase I/II study of StarGen, a
gene-based treatment for Stargardt’s disease. The first patient in this study was treated this month at
the Oregon Health & Science University’s Casey Eye Institute (Portland). StarGen has received
Orphan Drug Designation in the United States and Europe, Oxford said.
http://www.prooftalmoclinica.com.br/site
30/09/2016 21:12:17 / Page 1